Related Experiment Video
Updated: Jun 7, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
[Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data
B Siegmund1, H Pollmann, H Richter
1Institut für Thrombophilie und Hämostaseologie, Praxis Dr. med. Hartmut Pollmann, Loerstraße 19, 48143 Münster. ith@haemophilie-zentrum.de
Unlabelled:
In a retrospective study 118 haemophilia A patients from two treatment centres (Berlin and Muenster) were evaluated with respect to safety, i. e. inhibitor development, and efficacy of bleeding control of recombinant FVIII products. During approx. 57 thousand injections with more than 87 million I.U. rFVIII no de novo inhibitor was observed in patients previously treated with pFVIII after switch to a recombinant product. A total of 75 thousand injections with more than 111 million I.U. FVIII had been applied during the investigation period of 14 years. Before as well as after switch of the product type bleeding episodes could be controlled with one to two injections per bleed.
Conclusion:
According to our results equal safety and efficacy of plasma derived and recombinant FVIII products can be assumed.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Inhibitors of Viral Protein Synthesis
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Inhibitors Of Virion Release

